Otsuka Holdings Co., Ltd.

Overview

Otsuka Holdings Co., Ltd. (TSE: 4570) is a Japanese pharmaceutical company headquartered in Tokyo, Japan, founded in 2010 through the restructuring of Otsuka Pharmaceutical Co., Ltd. Otsuka is known for its innovative research in psychiatry, neurology, and oncology, with a strong focus on CNS disorders[@otsuka2024].

Otsuka has developed several important medications for neurological and psychiatric conditions and continues to invest in neurodegenerative disease research, particularly for Parkinson's disease and Alzheimer's disease. The company operates globally with 69 locations worldwide and generated approximately ¥1.74 trillion in revenue in 2022[@wikipedia2024].

Funding

• IPO: 2010 (TSE: 4578)
• Market Cap: ~$30B (2026)
• 2022 Revenue: ¥1.74 trillion (~$12B)
• Operating Income: ¥150.32 billion (2022)

History and Evolution

Otsuka Pharmaceutical was founded in 1964 by Toshihiko Otsuka. The company grew to become one of Japan's leading pharmaceutical companies with a focus on innovative medicines[@wikipedia2024].

Overview

Otsuka Holdings Co., Ltd. (TSE: 4570) is a Japanese pharmaceutical company headquartered in Tokyo, Japan, founded in 2010 through the restructuring of Otsuka Pharmaceutical Co., Ltd. Otsuka is known for its innovative research in psychiatry, neurology, and oncology, with a strong focus on CNS disorders[@otsuka2024].

Otsuka has developed several important medications for neurological and psychiatric conditions and continues to invest in neurodegenerative disease research, particularly for Parkinson's disease and Alzheimer's disease. The company operates globally with 69 locations worldwide and generated approximately ¥1.74 trillion in revenue in 2022[@wikipedia2024].

Funding

• IPO: 2010 (TSE: 4578)
• Market Cap: ~$30B (2026)
• 2022 Revenue: ¥1.74 trillion (~$12B)
• Operating Income: ¥150.32 billion (2022)

History and Evolution

Otsuka Pharmaceutical was founded in 1964 by Toshihiko Otsuka. The company grew to become one of Japan's leading pharmaceutical companies with a focus on innovative medicines[@wikipedia2024].

Key milestones:

• 1921: Otsuka Seiyaku (predecessor company) established
• 1964: Founded as Otsuka Pharmaceutical Co.
• 1974: Launch of Merital (antipsychotic)
• 1996: Launch of Pletaal (antiplatelet)
• 2010: Holding company restructuring
• 2013: Acquisition of Astex Pharmaceuticals for $886 million[@astex2013]
• 2014: Acquisition of Avanir Pharmaceuticals for $3.5 billion[@avanir2014]
• 2017: Acquisition of Neurovance Inc. for $250 million
• 2019: Acquisition of Visterra
• 2023: Acquisition of Mindset Pharma Inc. for $58.6 million
• 2024: Acquisition of Jnana Therapeutics Inc.

Corporate Structure

Otsuka Holdings operates through multiple subsidiaries focused on different therapeutic areas:

Key Subsidiaries

• Otsuka Pharmaceutical Co., Ltd. — Core pharmaceutical business
• Otsuka America, Inc. — US operations
• Avanir Pharmaceuticals — CNS focus (acquired 2014)
• Astex Pharmaceuticals — Cancer and CNS (acquired 2013)
• Visterra — Biologics (acquired 2019)
• Mindset Pharma Inc. — Psychedelic therapeutics (acquired 2023)
• Jnana Therapeutics — Protein degradation (acquired 2024)

Neuroscience Pipeline

Otsuka maintains a significant CNS portfolio with both approved products and development programs.

Approved CNS Products

| Drug | Indication | Mechanism | Notes |
|------|------------|-----------|-------|
| Abilify (aripiprazole) | Schizophrenia, bipolar disorder | Dopamine D2 partial agonist | Top-selling antipsychotic |
| Rexulti (brexpiprazole) | Schizophrenia, major depressive disorder | Serotonin-dopamine activity modulator | Developed with Lundbeck |
| Lybalvi (olanzapine/samidorphan) | Schizophrenia, bipolar disorder | D2 antagonist + opioid antagonist | Opioid receptor modulation |
| Rejoyn | Major depressive disorder | Novel mechanism | Recently approved |

Pipeline Programs in Neurodegeneration

| Drug | Indication | Phase | Mechanism | Notes |
|------|------------|-------|-----------|-------|
| S-474445 | Alzheimer's disease | Phase 1 | Amyloid aggregation inhibitor | Via Shionogi partnership |
| ATM-AkD | ALS | Preclinical | SOD1 targeting | Gene therapy approach |
| ASP-0742 | Parkinson's disease | Phase 1 | Novel target | In development |

Psychiatric Pipeline

| Drug | Indication | Phase | Notes |
|------|------------|-------|-------|
| TS-142 | Treatment-resistant depression | Phase 2 | Novel mechanism |
| SEP-4199 | Bipolar depression | Phase 3 | Amino acid derivative |

Research Focus Areas

Otsuka's neuroscience research focuses on:

Strategic Partnerships

Otsuka maintains key partnerships in the neuroscience space:

• Lundbeck — Co-development of Rexulti and other CNS drugs
• Shionogi — Collaboration on Alzheimer's pipeline (S-474445)
• Various academic collaborations — Including work with NIH and European institutions

Market Position

Otsuka is one of the leading CNS pharmaceutical companies globally:

• Ranked among top 20 global pharmaceutical companies by revenue
• #2 in Japanese pharmaceutical market
• Leader in schizophrenia treatment with Abilify franchise
• Growing presence in neurodegenerative diseases

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Schizophrenia](/diseases/schizophrenia)
• [Aripiprazole](/entities/aripiprazole)
• [Brexpiprazole](/entities/brexpiprazole)

References